Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene

被引:30
作者
Asou, H
Suzukawa, K
Kita, K
Nakase, K
Ueda, H
Morishita, K
Kamada, N
机构
[1] HIROSHIMA UNIV, SCH MED,NUCL MED & BIOL RES INST, DEPT CANC CYTOGENET,MINAMI KU, HIROSHIMA 734, JAPAN
[2] HIROSHIMA UNIV, SCH MED, DEPT PEDIAT, MINAMI KU, HIROSHIMA 734, JAPAN
[3] NATL CANC CTR, RES INST, DIV BIOL, CHUOU KU, TOKYO 104, JAPAN
[4] MIE UNIV, SCH MED, DEPT INTERNAL MED 2, TSU, MIE 514, JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1996年 / 87卷 / 03期
关键词
leukemia; cell line; AMLMO; t(3; 7); EVI1;
D O I
10.1111/j.1349-7006.1996.tb00216.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A novel human leukemia cell line (Kasumi-3) was established from the blast cells of a 57-year-old man suffering from myeloperoxidase-negative acute leukemia. The cell line had five distinctive features, as follows. 1) Flow cytometric analyses showed cell surface expression of CD7, CD4, CD13, CD33, CD34, HLA-DR and c-Kit. This phenotype is compatible with that of acute myelocytic leukemia cells with the M0 subtype in the French-American-British classification. 2) Kasumi-3 cells carried chromosomal abnormalities of t(3;7)(q27:q22), del(5)(q15), del(9)(q32), and add(12)(p11). The break-point of 3q27 was located near the EVI1 gene, and a high level of expression of the EVI1 gene was observed. 4) Kasumi-3 cells treated with TPA showed maturation to monocytic lineage. 5) Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating or stem cell factor induced the proliferation of Kasumi-3 cells. Thus, the Kasumi-3 cell line shows the characteristic features of undifferentiated leukemia. It should, therefore, be useful both for studying the biological characteristics of acute myelogenous leukemia M0 subtype and for investigating the role of the EVI1 gene in leukemogenesis.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 20 条
  • [1] ASOU H, 1991, BLOOD, V77, P2031
  • [2] BASSAN R, 1992, CANCER, V69, P396, DOI 10.1002/1097-0142(19920115)69:2<396::AID-CNCR2820690220>3.0.CO
  • [3] 2-E
  • [4] PROPOSAL FOR THE RECOGNITION OF MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-MO)
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (03) : 325 - 329
  • [5] BITTER MA, 1985, BLOOD, V66, P1362
  • [6] CYTOGENETIC PROFILE OF MINIMALLY DIFFERENTIATED (FAB M0) ACUTE MYELOID-LEUKEMIA - CORRELATION WITH CLINICOBIOLOGIC FINDINGS
    CUNEO, A
    FERRANT, A
    MICHAUX, JL
    BOOGAERTS, M
    DEMUYNCK, H
    VANORSHOVEN, A
    CRIEL, A
    STUL, M
    DALCIN, P
    HERNANDEZ, J
    CHATELAIN, B
    DOYEN, C
    LOUWAGIE, A
    CASTOLDI, G
    CASSIMAN, JJ
    VANDENBERGHE, H
    [J]. BLOOD, 1995, 85 (12) : 3688 - 3694
  • [7] FONATSCH C, 1994, LEUKEMIA, V8, P1318
  • [8] HAYASHI Y, 1993, INT J HEMATOL, V57, P124
  • [9] KITA K, 1993, BLOOD, V81, P2399
  • [10] KURTZBERG J, 1989, BLOOD, V73, P381